A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched. Studies were included if they had evaluated any single agent or combination of treatments for adult patients with relapsed/refractory MCL who had received ! 1 previous line of therapy. Seven RCTs were identified. Only 1 treatment appeared in > 1 trial; therefore, the results from each trial could not be quantitatively pooled for meta-analysis. The lack of common comparators, differences in baseline characteristics and inclusion and exclusion criteria, and variances in the response criteria used to measure outcomes made comparison of the results difficult. Although the direction of effect for progression-free survival (PFS) and overall survival (OS) was in favor of the experimental drug in all trials, the difference in PFS was statistically significant in 5 and OS in 2. None showed statistical significance for both. A noticeable lack of RCTs evaluating treatments for patients with relapsed/ refractory MCL made meaningful comparisons of effectiveness across trials rather difficult. This trend continues, because all, bar 1, of the 85 ongoing trials in this area are single-arm studies. RCTs are required to enable better evaluation of the optimal treatment regimen for this group of patients.
Introduction
Mantle cell lymphoma (MCL) is a rare B-cell malignancy belonging to the non-Hodgkin lymphoma (NHL) group of diseases. 1 MCL represents 3% to 10% of all newly diagnosed NHL cases, 2, 3 with an incidence of approximately 1 per 100,000 persons in Europe 4 and the United States. 5 MCL more commonly affects men, with a median age at presentation of 65 years 2 and is typically at an advanced stage at diagnosis, Ann Arbor stage III and IV. 6 The hallmark of MCL is the chromosomal translocation t(11;14)(q13;q32), resulting in overexpression of the cell cycle protein cyclin D1 and cell cycle dysregulation. 7 MCL has 2 main variants.
Classic MCL is the more common form 2 and has an overall survival (OS) of approximately 4.5 years. The blastoid variant of MCL is rarer but has been associated with a more aggressive clinical course and poorer prognosis, with an OS of approximately 15 months. 8 MCL frequently has an aggressive clinical course. Although initial therapy can achieve high overall response rates (ORRs) of 60% to 97%, 9 these tend to be short lived, and most patients will eventually develop relapse and die of their disease. Some patients, however, have a more indolent form of MCL. Although it is difficult to identify this group, some markers (eg, SOX11 negativity) might help to distinguish this indolent form from a more aggressive phenotype. Ongoing research in the United Kingdom 10 aims to characterize the differences in a prospective trial. Some clinicians have now adopted a "watch and wait" management approach with these patients if they are asymptomatic. 4 The first-line treatment options will depend on the age and fitness of the patient. Intensive frontline cytarabine-based treatments are reserved for younger, fitter patients because of their associated toxicity and are commonly consolidated with autologous transplantation.more frail at presentation; thus, this approach is not feasible. A number of immunochemotherapy options are available for this group of patients, 4 including B-R (bendamustine, rituximab), R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone) regimens, with response rates ranging from 60% to 95% and a median progressionfree survival (PFS) of 5 years. Rituximab maintenance also plays a role in sustaining the response after R-CHOP induction. 11 For the more frail patients who are unsuitable for immunochemotherapy,
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Materials and Methods
The review method was predefined in a protocol available in the Supplemental Data section (available in the online version) and registered in the Prospero website (available at: https://www.crd. york.ac.uk/PROSPERO/). Randomized controlled trials (RCTs) were included if they met the following criteria: (1) study population, adult patients with R/R MCL who had received ! 1 previous line of therapy and not eligible for intensive treatment or transplantation; (2) intervention, any single agent or combination of agents, including chemotherapy, immunotherapy, immunochemotherapy, targeted agents, excluding intensive treatment and transplantation; (3) comparator, any single agent or agents, as stated; and (4) outcomes, OS, PFS, ORR, and safety. Electronic searches were undertaken in Medline, Embase, and the Cochrane Library from January 1994 (MCL was accepted as a separate entity in 1994 14 Tables 1 and 2 (available in  the online version) . No language restrictions were used in the search.
Two reviewers (M.P. and M.K.) independently screened the search results for potential inclusion and exclusion using the title and abstract, with full paper copies obtained to confirm inclusion in the review. The final decision for the inclusion of articles was determined by agreement between the 2 reviewers.
Results
A total of 1746 articles were identified from the search as outlined in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram (Figure 1 ). After 430 duplicates were removed, 1316 articles were initially screened for inclusion from the title and abstract, with 27 published articles retrieved for full text screening. Seven RCTs met the inclusion criteria and were included in the present review. [15] [16] [17] [18] [19] [20] [21] Full agreement had been reached between the 2 reviewers regarding the included articles. The concordance between reviewers resulted from both the clearly defined criteria and the paucity of trials available in this setting. A summary of the trial design for the included trials is provided in Table 1 , with the treatment regimens for each trial listed in Table 2 . The follow-up duration among the trials varied, with the shortest median follow-up of 15.9 months in the trial conducted by Trneny et al 21 and the longest median follow-up of 96 months reported by Rummel et al. 20 All 3 trials that had included a variety of NHL subtypes 16, 17, 20 reported separate outcomes for the MCL subpopulation and were included in the present review. Only 1 treatment, temsirolimus, appeared in > 1 trial. Data were extracted from the articles by 1 reviewer (M.P.) and were checked by a second reviewer (M.K.). The study and patient characteristics and the details of the intervention and control were extracted. The outcomes data collected included OS, PFS, tumor responses, and data on safety, restricted to grade 3 and 4 hematologic toxicity.
Only a descriptive analysis of the included trials was feasible owing to the heterogeneity of the study populations and interventions.
Quality Assessment of Studies
The quality of each trial was evaluated using the Cochrane Collaboration's tool for assessing the risk of bias. 22 Assessment of the blinding of participants and personnel was not applicable, because all trials were open label and were therefore listed as unclear owing to the restrictions of choice within the tool. A full assessment of each trial is given in Supplemental bias because of differences in the baseline characteristics between the 2 groups and because they did not report prespecified outcomes. A summary of the risk of bias is shown in Figure 2 .
Baseline Characteristics
The inclusion criteria were broadly similar among the trials, with a couple of notable differences. Hess Table 3 and were generally well balanced between the treatment arms in most trials. Three trials 18, 19, 21 reported an imbalance in some baseline characteristics. In 1 study, 19 the treatment groups differed with respect to blastoid variant, the median number of previous lines of treatment, and the use of previous bortezomib therapy. Another study 18 differed with respect to the proportion of male patients, interval since diagnosis, and previous rituximab. The third study differed with respect to tumour burden, bulky disease, lactate dehydrogenase levels, number of previous therapies, and number of patients with refractory disease. 21 
Effectiveness of Treatments
The PFS, OS, and ORRs reported for MCL patients in the included trials are summarized in Table 4 . All the trials reported an improvement in PFS with the experimental drug, with the difference statistically significant in all, except for 2 of the trials. 16 marginal zone lymphoma, 8% had lymphoplasmacytic lymphoma, and 1% had low-grade disease, unclassified. A maximum of 6 cycles of either chemotherapy combination was administered to 230 patients. The protocol was amended during the course of the trial to include rituximab maintenance therapy for patients who had responded to B-R or F-R, because maintenance rituximab treatment had been approved for patients with FL. In patients with MCL, the improvement in PFS was statistically significant in the B-R arm (HR, 0.45; 95% CI, 0.22-0.76; P ¼ .01), with a median PFS of 17.6 months achieved with B-R compared with 4.7 months with F-R. An improvement in median OS was also observed (B-R group, 35.3 months vs. 20.9 months for the F-R group; P ¼ not reported). The effect of maintenance rituximab was not reported for the MCL patients. A superior ORR for the MCL patients receiving B-R was achieved (70.8% vs. 26.1%). Both the CR rate (37.5% vs. 13%) and the PR rate (33.3% vs. 13%) were substantially greater for the MCL patients treated with B-R compared with those treated with F-R.
Trneny et al 21 
Safety
A summary of grade ! 3 hematologic toxicities observed in the trials is presented in Figure 3 . Patients treated with ibrutinib had a longer duration of treatment exposure compared with the control arm in the trial by Dreyling et al 15 (14.4 vs. 3 months), with a mean relative dose intensity of 99.9% for ibrutinib versus 81.8% for temsirolimus. Adverse events caused treatment discontinuation and dose reductions in 6% and 4% of patients in the ibrutinib arm compared with 26% and 43% in the comparator group, respectively. The median duration of temsirolimus 175/75-mg treatment was more than double that of IC (12 vs. 5 weeks) in the trial by Hess et al. 19 Significantly greater rates of thrombocytopenia and anemia were observed with temsirolimus. In contrast, leukopenia was more frequent with IC chemotherapy than with higher dose temsirolimus (all grades, 15% vs. 40% with IC), as was neutropenia (all grades, 24% vs. 40% with IC). Of the patients in the temsirolimus 175/75-mg arm, 22% discontinued treatment because of an adverse event compared with 11% in the IC arm. The frequency of grade 3/4 hematologic toxicities was comparable across both treatment groups in the trial by Forstpointner et al, 16 except for lymphocytopenia, which was more common across grades 1 to 4 in the R-FCM arm than in the FCM arm. The extended use of rituximab during the maintenance phase of the trial 17 did not result in any significant differences in the adverse events between the 2 arms. Furtado et al 18 reported a similar rate of grade ! 3 thrombocytopenia between the 2 arms. However, a significant increase in the rate of grade ! 3 neutropenia was observed in the experimental arm, which translated to a greater rate of febrile neutropenia with the V-CHOP regimen. Non-neutropenic infection rates were also higher; however, these were primarily low grade. The B-R and F-R combinations were both well tolerated by patients in the trial by Rummel et al. 20 The dose intensity was 96.3% in the B-R group and 99.5% in the F-R arm, indicating good tolerability for both regimens. Rates of 2-3 previous therapies versus 4-7 previous therapies. c Duration < 3 y versus > 3 y. Dose reductions were more common in the lenalidomide group (41% vs. 17%), 21 but discontinuations were more common in the IC group (5% vs. 16%). The rates of grade ! 3 neutropenia were greater in the lenalidomide arm, with febrile neutropenia reported in 6% of patients receiving lenalidomide compared with 2% of patients receiving IC. The rates of anemia were comparable, with the incidence of thrombocytopenia greater in the IC arm.
Unpublished and Ongoing Trials
The data from 4 trials [23] [24] [25] [26] were presented at the 58th annual meeting of the ASH held in San Diego from December 3 to 6, 2016. All 4 trials had assessed combinations of treatments for R/R MCL. [23] [24] [25] [26] All these trials were single-arm studies but give an indication of emerging potential future management approaches. 27 These improved ORR and CR rates would indicate a deeper response with the combination of therapies, which might, in time, translate to longer PFS and OS for patients. As of December 2016, 85 trials were ongoing (www.clinicaltrials. gov and www.clinicaltrialsregister.eu), aiming to recruit > 2300 patients with relapsed/refractory MCL to evaluate monotherapies and combinations of agents. Of these 85 trials, 53 are phase I or phase I/II trials, 26 are in phase II, 1 trial is phase III, and 1 trial is phase IV. The remaining 4 trials are either retrospective or stated as pilot studies, with no further details. Only the phase III trial is a RCT (Supplemental Table 4 ; available in the online version). Of the remaining 26 ongoing phase II trials, 13 are evaluating combinations of treatments and 13 are assessing monotherapies. Ibrutinib is included in 5 combination trials, lenalidomide in 3 combination studies, 1 of which is with bendamustine, and bortezomib is combined with additional treatments in 2 trials.
Discussion
No consensus has been reached about the standard of care for R/ R MCL and the current UK, 2 European Union, 4 20 In their trial, MCL patients receiving the combination of bendamustine and rituximab achieved a median PFS of 17.6 months. In contrast, patients with FL achieved a median PFS of 54.5 months with the same regimen. These were exploratory subgroup analyses; nevertheless, this highlights the need to evaluate treatments for a pure MCL population to draw clinically meaningful conclusions. It can be challenging to accrue a sufficient number of patients to a trial when the disease is rare, and collaborative research groups have been established because of this. Forstpointner et al 16 had only included 48 patients with MCL when further recruitment was halted owing to the significant advantage observed in the R-FCM arm, which had a mixed population of lymphoma subtypes. The trial by Furtado et al 18 had planned to recruit 90 patients. However, the trial was stopped early owing to a significant difference in survival observed at the first predetermined evaluation point; thus, only 46 patients were included. Neither trial was statistically designed for such small numbers; therefore, the statistical significance of the results could be unreliable. The median PFS observed with V-CHOP treatment was double that with CHOP alone in the trial by Furtado et al, 18 yet this did not achieve statistical significance. It is difficult to make meaningful comparisons of effectiveness across the included trials in the present review because the inclusion and exclusion criteria differed among the trials. The trial by Dreyling et al 15 excluded patients with an ECOG PS > 1. The remaining trials allowed patients with an ECOG PS of 0 to 2. [18] [19] [20] [21] Most trials included patients who had received ! 1 line of previous therapy 15, 16, 18, 20, 21 ; however, these previous therapies differed between the trials and might have had some impact on the outcomes achieved. Previous rituximab therapy could have introduced an outcome bias to those trials allowing previous exposure. Rule et al 31 demonstrated that the addition of rituximab to fludarabine-based chemotherapy in patients with newly diagnosed MCL improved OS, resulting in a reduction in the hazard of death by 31%. In addition, it has been suggested that previous bortezomib treatment sensitizes MCL to subsequent therapies. 32 Another baseline factor that could affect the outcomes include the interval from the initial diagnosis to randomization because the longer time might suggest that these patients had more indolent disease and could safely wait to start therapy. The proportion of patients with the more difficult to treat blastoid histologic type will also affect the outcomes. The split between patients with relapsed disease and those with refractory disease will influence the outcomes, because refractory disease is generally a harder-to-treat subtype. Additional factors that should be considered when comparing trials are the differences in the MCL international prognostic index scores, the proportion of patients with high Ki-67 scores, indicating more aggressive disease, and other biologic factors such as TP53 mutation or SOX11 status, which will affect the outcomes. The ideal would be to have these balanced between the arms of each trial, and stratification before randomization might achieve this. However, in a rare disease, this can be difficult to achieve in practice. The blastoid histologic type represents a small proportion of the total MCL population; it is important that patients with this subtype are included in trials to collect data on how they respond to various treatments. It would not be feasible to perform a trial of this subtype alone; therefore, imbalances in the baseline characteristics of this nature between treatment arms should be tolerated, acknowledging that they could affect the results. The response criteria by which outcomes were measured also differed among the studies. It is important that consistent definitions of endpoints are used to allow for comparisons among clinical trials. The 1999 IWG criteria 33 were revised in 2007 27 and eliminated the need for the response criterion, CR unconfirmed, and incorporated the assessment of extranodal disease. In a trial 23 recently presented at the 58th Annual Meeting of the ASH in 2016, 2 analyses were conducted within the same trial, 1 using the 1999 IWG criteria 33 The addition of rituximab to chemotherapy regimens for the treatment of MCL has been established in a number of trials. Included in the present review were the trials by Forstpointner et al, 16, 17 which demonstrated that the addition of rituximab to the combination of fludarabine, cyclophosphamide, and mitoxantrone, followed by rituximab maintenance for patients in remission improved the response rates and OS. Maintenance rituximab resulted in a greater proportion of patients experiencing ongoing remission for > 2 years. Because most patients with MCL are elderly, the tolerability of treatment is an important factor when comparing different therapies and should be evaluated on the per protocol population to accurately reflect the adverse events in patients actually receiving the drug. The grade ! 3 hematologic adverse event rates varied considerably among the included trials. The rates of grade ! 3 hematologic toxicities were low with the combination of bendamustine and rituximab and the combination of fludarabine and rituximab in the trial by Rummel et al, 20 with high-dose intensities achieved in both arms of the trial. Ibrutinib was also well tolerated, with low rates of myelosuppression despite a treatment exposure 3 times as long with ibrutinib than with temsirolimus 175/75 mg. The results from both of these trials suggest that temsirolimus at the approved dose of 175/75 mg is poorly tolerated. In the trial by Forstpointner et al, 17 it was encouraging to note that rituximab maintenance did not result in substantial additional treatment-associated hematologic toxicities, with grade ! 3 adverse event rates very similar between the maintenance and no maintenance arms. Some of the novel agents identified in the present review are being evaluated in the front-line setting, which will affect the choice of agent when these patients subsequently develop a relapse. A UK study 36 evaluating ibrutinib and rituximab against a rituximab and chemotherapy combination in patients with newly diagnosed MCL who are not eligible for intensive treatment is ongoing. The results are expected in 2022. In addition, the SHINE trial (a study of the Bruton tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantle cell lymphoma) is assessing the combination of ibrutinib with B-R in patients with newly diagnosed MCL. 37 A similar trial evaluating the combination of the second-generation BTK inhibitor, acalabrutinib, with B-R 38 is ongoing, with the results due in February 2021. If these prove to be successful, the paradigm for relapsed or refractory disease will shift, and subsequent trials for relapsed/refractory MCL will need to include patients who have received previous ibrutinib or acalabrutinib treatment. A Spanish trial 39 is evaluating the combination of ibrutinib and rituximab in patients with newly diagnosed indolent MCL. That trial is expected to report results in January 2023. Several trials [40] [41] [42] are evaluating the role of lenalidomide in the first-line setting, either combined with chemotherapy or as maintenance after chemotherapy induction. The E1411 trial 43 is evaluating the combination of bortezomib with B-R as induction therapy, followed by rituximab with or without lenalidomide as maintenance. The results are expected in March 2019. A number of new agents are being assessed for R/R MCL, either as monotherapy or combined with established treatments, including venetoclax (BCL-2 inhibitor), idelalisib, and buparlisib (PI3Kd inhibitors), the second-generation proteasome inhibitor carfilzomib, daratumumab (an anti-CD38 monoclonal antibody), and genetically engineered chimeric antigen receptor T-cells (CAR T-cells). All are currently being evaluated in single-arm trials.
As the landscape of treatment options for the management of R/ R MCL becomes more complicated, comparative studies will be required to evaluate the relative advantages of 1 treatment over another to ensure the optimal use of the available therapies. The protocol only permitted the inclusion of RCTs, because that study design provides the best evidence for the effectiveness of treatments. Single-arm trials might provide additional information to clinicians regarding the efficacy of treatment options for this rare disease; however, these are biased by the nature of their design. It is concerning that only 1 of the ongoing studies is an RCT. Careful consideration should be given to future trial designs to ensure that meaningful evaluation of effectiveness of treatments can be undertaken.
The challenging factor is that MCL remains a rare malignancy with a small pool of patients from which to recruit to trials. Collaboration between research groups and agreement of standards for clinical trials is essential. In addition to this, using adaptive trial designs to assess the relative merits of treatments could help in addressing this challenge. Multi-arm, multistage trials have been adopted in some therapeutic areas to allow the comparison of a number of novel treatments compared simultaneously to a shared control group. 44 This can result in the provision of answers to research questions more quickly and cost effectively with a smaller number of patients and might be a suitable approach to adopt for evaluating future treatments or combinations of treatments for MCL patients. The scarcity of high-quality RCTs of MCL highlights the difficulty in evaluating the comparative efficacy and safety of new therapies. Historical studies lack common comparators, exhibit differences in inclusion criteria, and have small sample sizes. Although prognostic indicators such as the simplified MCL international prognostic index score or blastoid variant were reported in some of the studies, none of the trials reported outcomes according to these important factors owing to the small numbers of patients in these groups. The original protocol intended to undertake a subgroup analysis for these prognostic indicators; however, owing to the lack of data, such an analysis was not possible. Nevertheless, the present review should help to guide treatment selection for elderly patients with R/R MCL unsuitable for intensive chemotherapy or transplantation.
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